T cells of patients with systemic sclerosis or Sjögren's disease display an aberrant metabolic state and memory phenotype in blood and lungs
- PMID: 40244816
- DOI: 10.1093/rheumatology/keaf198
T cells of patients with systemic sclerosis or Sjögren's disease display an aberrant metabolic state and memory phenotype in blood and lungs
Abstract
Objectives: Systemic sclerosis (SSc) and Sjögren's disease (SjD) are characterized by systemic inflammation. Although for both entities lymphocyte involvement is reported, the contribution of T-cell responses to lung manifestation of SSc and SjD remains elusive. Therefore, we aimed for systematically investigating T-cell responses in blood and lungs of patients with SSc or with SjD.
Methods: For deep T-cell characterization, blood and bronchoalveolar lavages (BALs) from patients with SSc (n = 38) or SjD (n = 36) and healthy controls (HC) (n = 34) were analyzed by spectral flow cytometry.
Results: Recirculating blood T cells of patients with SSc showed a significantly increased CD4+ terminally differentiated effector memory (TEMRA) compartment (P = 0.0171) and impaired mitochondrial fitness. In patients with SjD, blood CD8+ T cells were overall reduced and showed an increased expression of CD25 on memory subsets. CD8+ T cells in BAL of patients with SSc- or SjD-associated interstitial lung disease (ILD) expressed significant levels of CD69 and PD1, displaying an exhausted phenotype. In addition, conventional dendritic cells type 2 are highly activated and express increased levels of HLA-DR in BALs of patients with ILD.
Conclusion: In patients with SSc-ILD and SjD-ILD, a disturbed T-cell memory differentiation combined with an exhausted phenotype and reduced metabolic fitness point towards sustained T-cell receptor engagement and chronic stimulation. Thus, the retrieved data indicate a significant involvement of T cells in the disease pathology of SSc- and SjD-associated ILD.
Keywords: Sjögren’s disease; T cells; T-cell exhaustion; dendritic cells type 2; immunomodulation; interstitial lung disease; mitochondrial fitness; systemic autoimmune rheumatic disease; systemic sclerosis; terminally differentiated effector memory.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Interleukin-32-expressing CD4+ T cells are a potentially pathogenic subset in systemic sclerosis with interstitial lung disease.Respir Investig. 2025 Sep;63(5):829-837. doi: 10.1016/j.resinv.2025.06.008. Epub 2025 Jul 4. Respir Investig. 2025. PMID: 40617174
-
Clinical Course and Outcomes in Patients with Sjögren's Associated Interstitial Lung Disease.Semin Respir Crit Care Med. 2025 Jun;46(3):281-287. doi: 10.1055/a-2578-4335. Epub 2025 May 30. Semin Respir Crit Care Med. 2025. PMID: 40446838
-
Identification of Pathogenic PD-1+CD8+ T Cells for Effective Chimeric Antigen Receptor Therapy in a Murine Model of Sjögren Disease.Arthritis Rheumatol. 2025 Aug;77(8):1026-1040. doi: 10.1002/art.43144. Epub 2025 Apr 30. Arthritis Rheumatol. 2025. PMID: 40026078
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article.
-
Systemic sclerosis at the crossroad of polyautoimmunity.Autoimmun Rev. 2013 Sep;12(11):1052-7. doi: 10.1016/j.autrev.2013.05.002. Epub 2013 Jun 19. Autoimmun Rev. 2013. PMID: 23791632
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials